DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...

Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose ...

In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day Dexcom G7 integrated continuous glucose monitor (CGM) in ...

Nanowear announced that it entered into a partnership with Dexcom to ingest glucose data from its latest continuous glucose ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.

Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and ...

"We conclude that the Dexcom 15-day G7 CGM is accurate and safe for use up to 15.5 days in adults with diabetes with a 27-minute warm-up," stated the investigators.

This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM). The letter cited multiple violations, including the failure to submit a premarket ...